Insys reaches settlement in opioid kickback case

Aug 08, 2018

Insys Therapeutics has agreed to pay $150 million to settle a case with the Department of Justice regarding sales of a powerful opioid.

According to the criminal and civil investigation, the company paid kickbacks to doctors who prescribed their under-the-tongue spray product, Subsys.

Under the terms of the settlement, Insys will pay $150 million over five years and then may need to make additional payments of up to $75 million, depending on certain unspecified circumstances.

“This is a very important step for our company to move forward and continue our transformative efforts to foster a compliant and ethical culture,” the company’s CEO, Saeed Motahari, said.

Read the full Bloomberg report. 

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments